Protect what matters for your eligible NVAF patients
State of the nation: Working together to prevent NVAF related strokes
3 min animation video
Ref
There is a 5 times greater risk of stroke in people with atrial fibrillation (AF) than the general population and AF-related strokes are more debilitating.
In England, it is estimated that there are 425,000 people living with undiagnosed and untreated AF, potentially exposing them to the devastating effects of stroke.
Hear expert speakers, Dr Jim Moore, Beverley Bostock and Dr Joe Martins, discuss the importance of the Detect, Protect and Perfect approach in identifying AF through opportunistic screening during long-term condition clinics, promptly initiating anticoagulation to mitigate stroke risk and optimising treatment individualised to the patient.
View Prescribing Information and Adverse Event Reporting.
Presented by: Dr Jim Moore , GP and GPwSI in Cardiology
View Prescribing Information and Adverse Event Reporting.
Presented by: Beverley Bostock, Advanced Nurse Practitioner
View Prescribing Information and Adverse Event Reporting.
Presented by: Dr Joe Martins, Consultant Interventional Cardiologist
Since its publication in 2019, The NHS Long Term Plan endeavours to prevent 150,000 strokes over the next 10 years. Adherence with the Detect, Protect and Perfect programme can help with achieving this goal.
Footnotes
NVAF, non-valvular atrial fibrillation; DOAC, direct oral anticoagulant.
* Rivaroxaban is to be used with caution in patients with CrCl 15 - 29 ml/min and in patients with renal impairment concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations. Use is not recommended in patients with CrCl < 15 ml/min.
** based on prospective real-world evidence where elderly is defined as 80 years or older, SAFIR-AC. Results of ROCKET-AF elderly patient sub-analysis were consistent with overall ROCKET-AF study.
RP-XAR-GB-5136 | February 2024
- expand_more